On June 17, 2022, the Suzhou Municipal Bureau of Agriculture and Rural Affairs conducted a "Preliminary Review of Biosafety" at Xishan Biotechnology Co., Ltd.

Image Name

2022.06.17

To safeguard national security, prevent and address biosecurity risks, protect people's lives and health, conserve biological resources and the ecological environment, promote the healthy development of biotechnology, and foster the building of a community with a shared future for humanity—thus achieving harmonious coexistence between humans and nature—on June 17, 2022, the Suzhou Municipal Bureau of Agriculture and Rural Affairs conducted "preliminary biosecurity reviews" at Xishan Biotechnology Co., Ltd. The assessment covered everything from the company's biosecurity system to on-site laboratory inspections, providing insights into the livestock and veterinary sectors as well as pathogenic microorganism laboratories.

This "Biosafety Audit" initiative responds to whether the nation is effectively safeguarding against and responding to threats posed by hazardous biological agents and related factors, ensuring that biotechnology is steadily advancing in a healthy manner, and confirming that people's lives, health, and ecosystems remain free from danger and unthreatened—thereby demonstrating the bio-sector's capacity to uphold national security and support sustainable development.

West Mountain

Previous article

From June 24 to 26, 2022, the assessment team from the China National Accreditation Service for Conformity Assessment (abbreviated as CNAS in English) conducted an expanded scope review of Suzhou Xishan Biotechnology Co., Ltd.

None

Next article

Previous article

None

Next article

None

More information

On May 10, 2025, our company's Nanoyuan facility successfully completed the filing process for the Suzhou P2 laboratory, becoming one of the first organizations in Suzhou city to receive official accreditation.

On May 10, 2025, our company's Nanoyuan facility successfully completed the filing process for the Suzhou P2 laboratory, becoming one of the first organizations in Suzhou city to receive official accreditation.

[Suzhou, May 10, 2025] Recently, our company’s Nano Park facility successfully completed the filing process for its P2 laboratory with the Suzhou Municipal Bureau of Agriculture and Rural Affairs, officially becoming one of the first animal pathogen microbiology laboratories in the entire Suzhou metropolitan area to receive approval under the newly implemented "Jiangsu Province Animal Pathogen Microbiology Laboratory Filing Management Measures" (effective February 1, 2025).

From September 1 to 2, 2024, our company successfully passed the CMA on-site assessment, further solidifying the authoritative recognition of our capabilities in laboratory animal testing.

From September 1 to 2, 2024, our company successfully passed the CMA on-site assessment, further solidifying the authoritative recognition of our capabilities in laboratory animal testing.

Recently, our company successfully passed the on-site expansion review for CMA accreditation, marking official recognition from a national authority of our professional expertise and robust quality management system in the field of laboratory animal testing. The review took place from September 1 to September 2, 2024, during which the expert panel conducted a comprehensive and rigorous assessment of our laboratory animal testing technologies, equipment, personnel, and management systems—ultimately confirming that we meet the relevant CMA standards.

August 6, 2024: Warmest congratulations to our company on successfully obtaining the veterinary drug production license and the veterinary drug GMP certificate.

August 6, 2024: Warmest congratulations to our company on successfully obtaining the veterinary drug production license and the veterinary drug GMP certificate.

August 6, 2024 – Our company has officially obtained the Veterinary Drug Production License and the Veterinary Drug GMP Certificate issued by the Ministry of Agriculture and Rural Affairs, marking that our company’s quality management system and technical capabilities in the veterinary drug manufacturing sector have met the nation’s stringent high-standard requirements. During this certification process, our immunology-based diagnostic product (Class B) production line successfully passed the on-site GMP inspection for veterinary drugs and was recognized as a qualified production line, laying a solid foundation for the company to further expand into the veterinary diagnostic reagent market.